ABSTRACT
Objective To investigate the clinical efficacy and safety of lyophilized recombinant human brain natriuretic peptide(rhBNP) in the treatment of patients with congestive heart failure (CHF).Methods 120 CHF patients were randomly divided into two groups.58 cases in the observation group were given lyophilized rhBNP,and 62 patients in the control group were given sodium nitroprusside.The clinical effect,changes of echocardiographic indicators and hemodynamic parameters,adverse reactions were observed.Results After treatment,the total effective rate of the observation group was 91.37％,which was significantly higher than that of the control group(x2 =4.23,P ＜ 0.05).The LVEF and NT-proBNP levels in observation group were (59.0 ± 8.2)％ and (535.4 ± 123.8)ng/L,which had higher improvement than control group (P ＜ 0.05).The incidence rate of adverse reactions between the two groups had no significant difference (P＞ 0.05).Conclusion Lyophilized rhBNP in the treatment of CHF has significant effect,and it is worthy of clinical application and promotion.
ABSTRACT
Transient receptor potential vanilloid 1(TRPV1)is a nonselective cationic channel,and can be activt-ed by capsaicin,protons and heat.TRPV1 plays a critical role in the initiation of neural inflammatory response and the pathway of pain signal transduction.As a new analgesics,TRPV1 antagonists block pain behaviors in models of inflammatory,neuropathic,and cancer pain.A number of pharmaceutical companies developed a range of TRPV1 antagonists with various structures.It was found that various chemotypes of TRPV1 antagonists would cause an increase in body temperature(hyperthermia),which may become concerns for their development.This article summarizes the recent progress in TRPV1 antagonists development and the relevant hyperthermia.